MX2015014608A - Novedosas moleculas de union biespecifica con actividad antitumoral. - Google Patents

Novedosas moleculas de union biespecifica con actividad antitumoral.

Info

Publication number
MX2015014608A
MX2015014608A MX2015014608A MX2015014608A MX2015014608A MX 2015014608 A MX2015014608 A MX 2015014608A MX 2015014608 A MX2015014608 A MX 2015014608A MX 2015014608 A MX2015014608 A MX 2015014608A MX 2015014608 A MX2015014608 A MX 2015014608A
Authority
MX
Mexico
Prior art keywords
amino acid
seq
bispecific binding
binding molecules
antitumoral activity
Prior art date
Application number
MX2015014608A
Other languages
English (en)
Inventor
Simon Brack
Julian Bertschinger
Dragan Grabulovski
Helen Hachemi
Richard Woods
Roger Santimaria
Ulrike Von Der Bey
Fabian Buller
Ulrich Wüllner
Kristina Klupsch
Irene Zbinden
Isabella Attinger-Toller
Susann König-Friedrich
Patricia Henne
Michela Silacci
Original Assignee
Covagen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covagen Ag filed Critical Covagen Ag
Publication of MX2015014608A publication Critical patent/MX2015014608A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)

Abstract

La presente invención se refiere a una molécula de unión biespecífica que se une de forma específica a (i) CD3 y (ii) a un antígeno diana superficial en las células cancerígenas, donde la molécula de unión comprende (a) un anticuerpo que se une de forma específica a CD3, y (b) un polipéptido derivado de Fyn-SH3 que se une a un antígeno diana superficial en las células cancerígenas, donde dicho polipéptido derivado de Fyn-SH3 consiste en la secuencia de aminoácidos de la SEQ ID NO: 1, con la condición de que (i) al menos un aminoácido dentro de las posiciones de aminoácidos 10 a 19 de la SEQ ID NO: 1 se encuentre sustituido, eliminado o agregado y (ii) al menos un aminoácido dentro de las posiciones de aminoácidos 29 a 36 de la SEQ ID NO: 1 se encuentre sustituido, eliminado o agregado, siempre que dicho polipéptido tenga al menos un 85% de identidad de secuencia con respecto a la secuencia de aminoácidos de la SEQ ID NO: 1, donde la determinación de la identidad excluye las posiciones de aminoácidos 12 a 17 y 31 a 34 de la SEQ ID NO: 1.
MX2015014608A 2013-04-19 2014-03-06 Novedosas moleculas de union biespecifica con actividad antitumoral. MX2015014608A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13164555 2013-04-19
PCT/EP2014/054390 WO2014170063A1 (en) 2013-04-19 2014-03-06 Novel bispecific binding molecules with antitumoral activity

Publications (1)

Publication Number Publication Date
MX2015014608A true MX2015014608A (es) 2016-03-03

Family

ID=48128216

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014608A MX2015014608A (es) 2013-04-19 2014-03-06 Novedosas moleculas de union biespecifica con actividad antitumoral.

Country Status (15)

Country Link
EP (1) EP2986630B1 (es)
JP (2) JP6694808B2 (es)
KR (1) KR20160002882A (es)
CN (1) CN105189544A (es)
AU (1) AU2014256037B2 (es)
BR (1) BR112015026143A2 (es)
CA (1) CA2908988A1 (es)
CL (1) CL2015003085A1 (es)
EA (1) EA201592006A1 (es)
HK (1) HK1214605A1 (es)
MX (1) MX2015014608A (es)
PH (1) PH12015502278A1 (es)
SG (1) SG11201508231UA (es)
WO (1) WO2014170063A1 (es)
ZA (1) ZA201507752B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
SG10201610416TA (en) 2012-06-13 2017-01-27 Incyte Corp Substituted tricyclic compounds as fgfr inhibitors
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as inhibitors of FGFR
UA120753C2 (uk) 2013-12-17 2020-02-10 Дженентек, Інк. Біспецифічне антитіло до сd3 та cd20
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX2020004108A (es) 2015-02-20 2022-01-03 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
FI126633B (en) 2015-07-10 2017-03-15 Next Biomed Therapies Oy Method of Preparation of a Library comprising Recombinant Derivatives of the SH3 Domain of Nephrocystin (NPHP1)
EP3541843A1 (en) 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
EA201992143A1 (ru) * 2017-04-24 2020-03-13 Икнос Сайенсиз Са Биспецифические антитела, перенаправляющие т-клетки, для лечения egfr-положительных раковых заболеваний
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
AU2018314236A1 (en) 2017-08-11 2020-03-19 Apterna Limited RNA aptamers against transferrin receptor (TfR)
WO2019033050A1 (en) * 2017-08-11 2019-02-14 City Of Hope BISPECIFIC MOLECULE FOR BINDING TO ANTIGEN
IL273119B2 (en) 2017-09-08 2023-10-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
JP2020534811A (ja) * 2017-09-08 2020-12-03 マベリック セラピューティクス， インコーポレイテッドＭａｖｅｒｉｃｋ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｆｃ領域を含有する条件的に活性化された結合部分
US20190153096A1 (en) 2017-10-02 2019-05-23 Covagen Ag Cd3/cd33 bispecific binding molecules
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
CA3089287A1 (en) 2018-02-08 2019-08-15 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclyl heterocycles as fgr suppressors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
EP4073111A1 (en) 2019-12-11 2022-10-19 Cilag GmbH International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
WO2021119505A1 (en) 2019-12-13 2021-06-17 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023201291A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
CN102869678A (zh) * 2009-08-27 2013-01-09 科瓦根股份公司 Il-17结合化合物及其医药用途
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
EP2576621B1 (en) * 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2

Also Published As

Publication number Publication date
PH12015502278A1 (en) 2016-02-01
WO2014170063A1 (en) 2014-10-23
JP6694808B2 (ja) 2020-05-20
AU2014256037A1 (en) 2015-10-29
ZA201507752B (en) 2017-03-29
CL2015003085A1 (es) 2016-06-03
EP2986630B1 (en) 2018-08-15
AU2014256037B2 (en) 2017-09-21
EA201592006A1 (ru) 2016-03-31
CA2908988A1 (en) 2014-10-23
BR112015026143A2 (pt) 2017-10-17
EP2986630A1 (en) 2016-02-24
JP2016516789A (ja) 2016-06-09
SG11201508231UA (en) 2015-11-27
KR20160002882A (ko) 2016-01-08
HK1214605A1 (zh) 2016-07-29
CN105189544A (zh) 2015-12-23
JP2019106997A (ja) 2019-07-04

Similar Documents

Publication Publication Date Title
PH12015502278A1 (en) Novel bispecific binding molecules with antitumoral activity
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
MX2014005108A (es) Constructos de polipeptidos y sus usos.
MX2018004362A (es) Anticuerpos anti-lag3 y sus usos.
MX2017001401A (es) Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas.
MX2017001403A (es) Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX353382B (es) Moleculas de union polipeptido de larga duracion.
MX2014001375A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2016004579A (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
UA106607C2 (uk) Білки специфічного зв'язування і їх застосування
MX357505B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2013015393A (es) Inmunocitosinas basadas en un dominio sushi de il-15 y de il-15ra.
MX2016001555A (es) Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
NZ703653A (en) Anti-fap antibodies and methods of use
EA201790934A1 (ru) ВАРИАНТЫ ИНТЕРФЕРОНА α2b
MX359384B (es) Conjunto mejorado de anticuerpos bisespecificos.
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
UA106458C2 (uk) Чутливий до сульфонілсечовини репресорний білок
NZ610091A (en) Antibodies
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
MX2022001942A (es) Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.
MX2016014409A (es) Produccion de proteinas heteromultimericas usando celulas de mamifero.